Cerus Corp
NASDAQ:CERS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.52
2.42
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CERS stock under the Base Case scenario is 1.55 USD. Compared to the current market price of 1.79 USD, Cerus Corp is Overvalued by 13%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cerus Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CERS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Cerus Corp
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cerus Corp
Balance Sheet Decomposition
Cerus Corp
Current Assets | 140.6m |
Cash & Short-Term Investments | 75.6m |
Receivables | 24.4m |
Other Current Assets | 40.7m |
Non-Current Assets | 48.9m |
PP&E | 16.4m |
Intangibles | 1.3m |
Other Non-Current Assets | 31.2m |
Current Liabilities | 54.3m |
Accounts Payable | 15.9m |
Accrued Liabilities | 18.1m |
Other Current Liabilities | 20.3m |
Non-Current Liabilities | 81.7m |
Long-Term Debt | 64.8m |
Other Non-Current Liabilities | 16.9m |
Earnings Waterfall
Cerus Corp
Revenue
|
197.9m
USD
|
Cost of Revenue
|
-78.1m
USD
|
Gross Profit
|
119.8m
USD
|
Operating Expenses
|
-131.6m
USD
|
Operating Income
|
-11.8m
USD
|
Other Expenses
|
-7.9m
USD
|
Net Income
|
-19.7m
USD
|
Free Cash Flow Analysis
Cerus Corp
USD | |
Free Cash Flow | USD |
CERS Profitability Score
Profitability Due Diligence
Cerus Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Cerus Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
CERS Solvency Score
Solvency Due Diligence
Cerus Corp's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Cerus Corp's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CERS Price Targets Summary
Cerus Corp
According to Wall Street analysts, the average 1-year price target for CERS is 3.98 USD with a low forecast of 2.53 USD and a high forecast of 5.25 USD.
Dividends
Current shareholder yield for CERS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CERS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.
Contact
IPO
Employees
Officers
The intrinsic value of one CERS stock under the Base Case scenario is 1.55 USD.
Compared to the current market price of 1.79 USD, Cerus Corp is Overvalued by 13%.